Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$3.2b

Apellis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:APLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Mar 25SellUS$139,789David WatsonIndividual5,569US$25.10
11 Feb 25SellUS$10,360Mark DelongIndividual363US$28.54
29 Jan 25SellUS$10,776Mark DelongIndividual365US$29.52
29 Jan 25SellUS$83,375Cedric FrancoisIndividual2,824US$29.52
29 Jan 25SellUS$24,357Nur NicholsonIndividual825US$29.52
29 Jan 25SellUS$20,519Adam TownsendIndividual695US$29.52
29 Jan 25SellUS$24,386Pascal DeschateletsIndividual826US$29.52
29 Jan 25SellUS$10,747Karen LewisIndividual364US$29.52
29 Jan 25SellUS$16,120Timothy SullivanIndividual546US$29.52
29 Jan 25SellUS$8,208Jeffrey EiseleIndividual278US$29.52
29 Jan 25SellUS$20,519David WatsonIndividual695US$29.52
22 Jan 25SellUS$42,474Mark DelongIndividual1,396US$30.43
22 Jan 25SellUS$39,279Jeffrey EiseleIndividual1,291US$30.43
22 Jan 25SellUS$33,346James ChopasIndividual1,096US$30.43
22 Jan 25SellUS$120,120Pascal DeschateletsIndividual3,948US$30.43
22 Jan 25SellUS$93,954Timothy SullivanIndividual3,088US$30.43
22 Jan 25SellUS$120,120Nur NicholsonIndividual3,948US$30.43
22 Jan 25SellUS$53,275Karen LewisIndividual1,751US$30.43
22 Jan 25SellUS$412,296Cedric FrancoisIndividual13,551US$30.43
22 Jan 25SellUS$101,104David WatsonIndividual3,323US$30.43
22 Jan 25SellUS$101,104Adam TownsendIndividual3,323US$30.43
21 Jan 25SellUS$21,420James ChopasIndividual715US$29.96
17 Jan 25SellUS$37,178Karen LewisIndividual1,241US$29.96
17 Jan 25SellUS$55,513Caroline BaumalIndividual1,853US$29.96
17 Jan 25SellUS$36,998Mark DelongIndividual1,235US$29.96
17 Jan 25SellUS$179,959Cedric FrancoisIndividual6,007US$29.96
17 Jan 25SellUS$22,469Pascal DeschateletsIndividual750US$29.96
17 Jan 25SellUS$64,260Nur NicholsonIndividual2,145US$29.96
17 Jan 25SellUS$65,938Adam TownsendIndividual2,201US$29.96
17 Jan 25SellUS$51,828Timothy SullivanIndividual1,730US$29.96
17 Jan 25SellUS$65,938David WatsonIndividual2,201US$29.96
13 Jan 25SellUS$45,895Mark DelongIndividual1,599US$28.70
13 Jan 25SellUS$7,577Jeffrey EiseleIndividual264US$28.70
13 Jan 25SellUS$65,670Pascal DeschateletsIndividual2,288US$28.70
13 Jan 25SellUS$179,302Cedric FrancoisIndividual6,247US$28.70
13 Jan 25SellUS$75,544Nur NicholsonIndividual2,632US$28.70
13 Jan 25SellUS$142,506David WatsonIndividual4,965US$28.70
13 Jan 25SellUS$77,065Adam TownsendIndividual2,685US$28.70
13 Jan 25SellUS$22,474James ChopasIndividual783US$28.70
13 Jan 25SellUS$45,895Karen LewisIndividual1,599US$28.70
06 Jan 25SellUS$95,215Caroline BaumalIndividual2,816US$33.81
23 Dec 24SellUS$2,085Jeffrey EiseleIndividual63US$33.09
11 Dec 24SellUS$171,175David WatsonIndividual5,000US$34.24
16 Sep 24SellUS$6,952James ChopasIndividual192US$36.21
03 Sep 24SellUS$21,720James ChopasIndividual550US$39.49

Insider Trading Volume

Insider Buying: APLS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of APLS?
Owner TypeNumber of SharesOwnership Percentage
State or Government45,9150.0317%
Individual Insiders4,324,5222.98%
VC/PE Firms12,806,3428.83%
Hedge Funds24,113,06516.6%
Institutions103,696,02671.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 91.81% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.2%
The Morningside Group Limited
12,806,342US$321.6m0%15.62%
9.74%
Avoro Capital Advisors LLC
12,222,222US$306.9m10%4.19%
9.47%
EcoR1 Capital, LLC
11,890,843US$298.6m0%14.41%
9.4%
Wellington Management Group LLP
11,800,849US$296.3m-24.2%0.05%
8%
The Vanguard Group, Inc.
10,046,025US$252.3m2.35%no data
7.57%
Morgan Stanley, Investment Banking and Brokerage Investments
9,504,951US$238.7m190%0.03%
5.16%
BlackRock, Inc.
6,477,896US$162.7m4.61%no data
3.61%
State Street Global Advisors, Inc.
4,525,155US$113.6m12%no data
3.41%
Deep Track Capital, LP
4,274,921US$107.3m-2.86%3.91%
2.4%
Octagon Capital Advisors LP
3,006,980US$75.5m0%13.73%
2.24%
Invus Financial Advisors, LLC
2,816,258US$70.7m30%3.64%
2.23%
UBS Asset Management AG
2,799,626US$70.3m454%0.01%
2.2%
Jennison Associates LLC
2,760,404US$69.3m51.6%0.04%
1.69%
FMR LLC
2,127,404US$53.4m-26.6%no data
1.67%
Braidwell LP
2,098,866US$52.7m-32.8%2.56%
1.47%
AQR Capital Management, LLC
1,840,510US$46.2m127%0.06%
1.47%
Geode Capital Management, LLC
1,838,952US$46.2m1.57%no data
1.39%
Deutsche Asset & Wealth Management
1,750,839US$44.0m1.65%0.01%
1.38%
Cedric Francois
1,736,870US$43.6m1.5%no data
1.32%
Point72 Asset Management, L.P.
1,660,348US$41.7m0%0.09%
1.26%
Polar Capital Holdings Plc
1,577,175US$39.6m45.8%0.14%
1.25%
Bank of America Corporation, Asset Management Arm
1,571,234US$39.5m173%0.01%
1.14%
Boxer Capital Management, LLC
1,426,000US$35.8m0%3.17%
1.1%
National Bank Investments Inc.
1,385,600US$34.8m266,000%0.04%
1.02%
CIBC World Markets Corp., Brokerage and Security Investments
1,285,300US$32.3m0%0.19%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 03:59
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 35 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Michael UlzBaird
Ishan MajumdarBaptista Research